DALLAS, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”) is engaged in the development, marketing and sale of a variety of men's health products. This is a company we are focusing on. The company, which offers wellness products through a secure telemedicine platform, including its proprietary erectile dysfunction (ED) treatment brand Mango, is offering affiliate marketing programs through its newly designed website www.MangoRevenue.com. We are pleased to announce the official launch of .
“Affiliate marketing programs have been shown to significantly increase trust and recognition when properly marketed and executed properly. This strategy will further increase brand recognition and notoriety for our MangoRx brand. We believe this will continue to grow,” said CEO and co-founder Jacob Cohen. Mango Rx. “Because affiliate marketers are compensated based on sales and performance, this new and dynamic channel offers the opportunity to drive additional sales while reducing the burden of upfront capital traditionally spent on digital marketing and advertising. We believe that if an affiliate marketing program is properly executed and marketed, it can generate approximately 20% or more of a company's total revenue.”
According to recent affiliate marketing research, the global affiliate marketing industry is worth more than $17 billion, and the market size is expected to grow to $27.78 billion by 2027. Additionally, 81% of brands use affiliate programs to increase brand awareness and increase sales. These affiliate marketing programs account for 16% of all internet orders in the United States. Big brands derive between 5% and 25% of their total online sales from affiliate marketing, and 20% of brand marketers claim that affiliate marketing is their most profitable channel.
We partner with one of the top marketing agencies and software providers in the affiliate marketing industry to ensure we have all the building blocks in place to accelerate future sales growth.
MangoRx chooses Impact Radius (www.impact.com), a company trusted by thousands of major global brands including Kohl's, Best Buy, Uber, Microsoft, Target, Levi's, Adidas, Yeti, Gap and more Did. As the best affiliate automation and influencer management platform. Impact Radius offers state-of-the-art backend software management for affiliate marketing programs and an actively managed recruitment database of over 7 million influencers interested in helping emerging brands blossom and thrive We have cooperated with companies that. Impact Radius also manages the toolkit for affiliate marketing partners.
Additionally, MangoRx has partnered with Hamster Garage (www.hamstergarage.com), a partnership and affiliate management agency, to help build and manage MangoRx's partnership program. Hamster Garage has underwritten over 40,000 affiliate marketing relationships with his partners, helping partners and clients raise more than $9.3 billion for him, and the average program increases overall project efficiency to his 300. % has improved. Hamster Garage coordinates and manages MangoRx's affiliate relationships to facilitate affiliate discovery and interest.
Mr. Cohen continued, “We absolutely believe that affiliate marketing is a new avenue to drive accelerated sales growth for MangoRx and our associates, and this is our top priority. We believe we have a premium product. We now have top-notch partners and a viable strategy to significantly increase our visibility and brand value. Further updates on this program coming soon We look forward to serving you.”
To learn more about the perks and benefits of the MangoRx Affiliate Marketing Program, please visit www.MangoRevenue.com.
About mango
Created using a special formula featuring the same active ingredients as Cialis™ (Tadalafil) or Viagra™ (Sildenafil), each part of the Mango formulation plays an important role in helping men achieve optimal performance. We believe the key to our success lies in our proprietary blend of ingredients used in our U.S. Food and Drug Administration (“FDA”) approved medicines. Mango contains a combination of sildenafil or tadalafil in addition to oxytocin and L-arginine, which have been traditionally used to treat sexual dysfunction.
Mango is a prescription drug that must be approved by your doctor. After an individual completes an online telehealth visit, our network of healthcare providers will review and approve the prescription if medically appropriate. Mango is a rapidly dissolving tablet (RDT) that is absorbed orally. For best results, it is recommended to consume mango at least 15 minutes before engaging in sexual activity. Sildenafil and tadalafil, one of the main ingredients in mango, typically have effects that last up to 4 and 36 hours, respectively.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men's health and wellness products and services via a secure telehealth platform. Historically, the company has identified its men's wellness telemedicine services and products as relevant to growth areas, particularly in the area of erectile dysfunction (ED). The company has developed a new brand of ED products under the brand name “Mango” (think “Man, Go!”).
For more information, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“Forward-Looking Statements”). ”). These forward-looking statements represent our current expectations or beliefs regarding future events and generally include the words “estimate,” “expect,” “predict,” “believe,” and “anticipate.” , can be identified using statements that include words such as “intends,” “anticipates,” “anticipates,” and “predicts.” “Plan,” “anticipate,” “anticipate,” “likely,” “intend,” “target,” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are beyond our control and may cause actual results to differ from those expressed or implied in the forward-looking statements. This could lead to a very different cause. our ability to obtain additional funds and generate revenue to support our operations; The risks associated with our ED products have not been and will not be approved by the U.S. Food and Drug Administration (“FDA”), and the FDA's clinical trials designed to prevent the possibility of severe patient One that does not benefit from the protocol. Injuries and deaths. the risk that the FDA may determine that the Company's planned product formulations do not qualify for exemptions under the Federal Food, Drug, and Cosmetic Act (the “FFDCA Act”) as provided in Section 503A; risks associated with related party relationships and contracts; data security breaches, malicious code, and/or hacker effects; our ability to generate competition and well-known brand names; Changes in consumer tastes and preferences. material changes and/or termination of relationships with key parties; Critical product returns from customers, product liability, recalls and litigation related to contaminated products or products found to pose health problems. our ability to innovate, expand our offerings and compete with competitors with greater resources; our reliance on related party transactions; the estimated size of the potential market for our technology and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, and our President, Jonathan Arango, collectively control a majority of the voting power in our company; risks related to the large number of public offerings, the volume of our stock, the impact of the sale of a significant number of our shares in the market, and the fact that a majority of our stockholders paid less for their shares than the offering price; recent initial public offerings; Our common stock in . the fact that the Company has a number of outstanding warrants to purchase common stock at a price of $1.00 per share; Its resale is registered under the Securities Act of 1933, as amended. our ability to build and maintain our brand; CYBERSECURITY, INFORMATION SYSTEMS, FRAUD RISKS AND PROBLEMS WITH OUR WEBSITE. changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations with which we must comply in connection with our operations, manufacturing, labeling and shipping; our dependence on third parties for the formulation and formulation of our ED products; our ability to establish or maintain relationships and/or relationships with third parties; potential safety risks associated with our Mango ED products, including the use of raw materials, the combination of such raw materials and their dosage; High inflation, rising interest rates, recessionary effects (including a potential recession), macroeconomic, geopolitical, health, and industrial trends, pandemics, acts of war (including the ongoing Ukraine/Russia conflict), and other major Scale crisis. our ability to protect our intellectual property rights; our ability to attract and retain key personnel to effectively manage our business; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhangs that could reduce the value of our common stock; volatility in the trading price of our common stock; general consumer sentiment and economic conditions that may affect the level of customer discretionary purchases of our products, such as a potential economic recession or global economic slowdown; Although we believe that our plans, intentions and expectations reflected in or implied by the forward-looking statements we make in this release are reasonable, we cannot guarantee that these plans, intentions and expectations will be achieved. there is no. Accordingly, such list should not be considered a complete compilation of all potential risks and uncertainties.
For more information about the potential factors that could affect our financial results, see “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors,” and “Management's Discussion and Analysis of Financial Condition and Results of Operations.” ” section from time to time. the Company's filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023; These filings are available below. www.sec.gov On our website, https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to us or our agents are expressly qualified in their entirety by the cautionary statement above. Other unknown or unpredictable factors may also materially adversely affect our future results. The forward-looking statements contained in this press release are made only as of the date of this press release. We cannot guarantee future results, activity levels, performance or achievements. Therefore, you should not place undue reliance on these forward-looking statements. Finally, we undertake no obligation to update these statements after the date of this release, except as required by law, and we undertake no obligation to update or update information created by third parties for which we do not pay a fee. We are not obligated to make any corrections. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media.
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
Or click here to find out why orange is the new blue:
https://www.mangorx.com
For public relations
Lucky Break Public Relations Department
sarah simpson
sahra@luckybreakpr.com
(323) 602-0091 extension 704
Information for investors
Mangoceuticals Investor Information
Email: investors@mangorx.com
Media inquiries
Phoenix MGMT Marketing & Consulting
info@phoenix-mediamarketing.com
sauce: Mangoceuticals Co., Ltd.
